Previous studies have reported that high expression of these genes is associated with poor prognosis in multiple cancers, including glioma, gastric cancer and colorectal cancer, and mediates resistance to HER2-positive breast cancer (25–29). Here, ERBB2 is linked to breast carcinoma.